Pivotal's scientific team is composed of respected researchers with numerous other drugs in clinical trials throughout the world. Our business team includes experienced professionals who have managed drug development through clinical trials to FDA approval. The Advisory Board consist of distinguished scientists and scientist/businessmen who are actively assisting Pivotal Biosciences.
Business TeamDimitri Villard, M.S.
Chairman of the Board, President
Executive Committee, Tech Coast Angels; former Director of investment banking firm SG Cowen; former Chairman/CEO, ArtistDirectTom Silberg
CEO, Stem Protein; former President of Abraxis Pharmaceutical Products, former COO of Tercica and Ligan Pharmaceuticals, 27 years at Hoffman-LaRoche.Stephen Flaim, Ph.D.
Tech Coast Angels, Board of Governors; former Sr. VP, Gallileo Labs, Rega BioSciences; VP, Alliance Pharmaceuticals; Division Director, Bristol-Meyers SquibbPaul Cossum, Ph.D.
Exec VP, ESSA Pharmaceuticals, former CEO Texas BioAlliance, Pro Acta; former EVP New Biotics, ISIS Pharmaceuticals
Science TeamAlan L. Epstein, M.D., Ph.D.
Professor, Dept. of Pathology, University of Southern California Keck School of Medicine
Developed a novel method to target necrotic cells in human cancers, published over 120 articles on cancer research, numerous awards
Pivotal's Scientific and Business Advisory Board consists of highly respected individuals in their scientific fields who provide an invaluable resource to Pivotal through the R&D process. Their collective experience includes domain expertise in the development and testing of new therapies for cancer, immunotherapy and vaccine development, infectious diseases, pharmacology, biophysics and structural biology at the USC Keck School of Medicine, M.D. Anderson Cancer Center/University of Texas, and The Mayo Clinic.
Scientific and Business Advisory Board
Robert Figlin, M.D., Chairman
Dr. Figlin is a former Professor at UCLA and a co-founder of Agensys.
Peter Anderson, M.D., Ph.D.
An expert on the development and testing of new therapies for cancer, especially in new formulations of IL-2 and methods to improve its half-life and delivery into patients.Elizabeth Grimm, Ph.D.
Professor of Cancer Biology, University of Texas, M.D. Anderson Cancer Center
A noted investigator of T-cell immunity who has devoted a large part of her career to the study and use of IL-2 for the treatment of cancer.Steven Richieri, M.B.A.
Senior VP, Banyan Biomarkers
20 year executive veteran in biotech R&D, with successful commercialization experience of biopharmaceuticals at PhotoThera, Egea BioSciences, Immune Response and other biotechnology companies.
Pivotal BioSciences, Inc.
Tel: (310) 734-4551
Pivotal BioSciences, Inc. © 2016. All Rights Reserved.